Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Exagen ( (XGN) ) is now available.
On July 17, 2025, Exagen Inc. announced the appointment of Chas McKhann to its Board of Directors, highlighting his extensive experience in the life sciences industry and previous leadership roles in companies acquired by Boston Scientific. This strategic move is expected to bolster Exagen’s growth and enhance its position in the autoimmune diagnostics market, aiming to drive strategic growth and create long-term value for patients, providers, and shareholders.
The most recent analyst rating on (XGN) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Exagen stock, see the XGN Stock Forecast page.
Spark’s Take on XGN Stock
According to Spark, TipRanks’ AI Analyst, XGN is a Neutral.
Exagen’s overall stock score is driven by strong technical indicators and strategic corporate actions that enhance financial flexibility. However, financial performance remains weak due to ongoing losses and valuation challenges.
To see Spark’s full report on XGN stock, click here.
More about Exagen
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring.
Average Trading Volume: 271,073
Technical Sentiment Signal: Buy
Current Market Cap: $148.2M
For an in-depth examination of XGN stock, go to TipRanks’ Overview page.